Side-by-Side Comparison
Ipamorelin vs Sermorelin: Mechanism, Evidence & Safety Compared
An evidence-based side-by-side look at how Ipamorelin and Sermorelin differ in mechanism, regulatory status, strength of the research base, and clinical application — compiled from the published literature and the FDA regulatory record.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
Also: NNC 26-0161
A selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin.
Also: Geref, GHRH(1-29)NH2
A growth hormone-releasing hormone analog with a long history of clinical use for GH deficiency diagnosis and therapy.
Side-by-side comparison
| Attribute | Ipamorelin | Sermorelin |
|---|---|---|
| Primary mechanism | Ghrelin Receptor Agonism | GHRH Receptor Agonism |
| FDA status | Banned from Compounding (Category 2) | FDA Approved |
| Evidence level | Emerging Clinical Evidence | Strong Clinical Evidence |
| Human trials | Yes (2+ indexed) | Yes (15+ indexed) |
| Studies indexed | 33 total (4 human, 18 animal) | 51 total (22 human, 15 animal) |
| Primary uses researched | Growth hormone release, Body composition, Sleep quality, Recovery | Growth hormone stimulation, Anti-aging, Sleep quality, Body composition |
| Administration routes | subcutaneous | subcutaneous |
| Molecular weight | 711.85 Da | 3357.93 Da |
| Amino acids | 5 | 29 |
| Category | growth hormone | growth hormone |
| WADA status | Prohibited | Prohibited |
Key differences
Mechanism. Ipamorelin acts primarily through ghrelin receptor agonism, while Sermorelin acts primarily through ghrh receptor agonism. This means they address different biological pathways even when targeting overlapping clinical goals.
Regulatory status. Ipamorelin is classified as banned from compounding (category 2); Sermorelin is classified as fda approved. Regulatory status drives availability, legality, and the standard of evidence required for specific therapeutic claims.
Evidence base. Sermorelin sits at a higher evidence level (L4) than Ipamorelin (L3) under PeptideMark's L1–L5 methodology.
Research focus. Published research on Ipamorelin has concentrated on growth hormone release, body composition, sleep quality. Research on Sermorelin has concentrated on growth hormone stimulation, anti-aging, sleep quality. There is meaningful overlap between the two research programs, which is why these compounds are frequently compared.
Safety snapshot
| Attribute | Ipamorelin | Sermorelin |
|---|---|---|
| Documented effects | 6 total | 6 total |
| Serious events | 0 | 0 |
| Common events | 1 | 1 |
| Black box warning | No | No |
| Contraindications | 3 listed | 3 listed |
| Drug interactions | 2 flagged | 2 flagged |
| Most common event | Injection site reactions | Injection site reactions |
Strengths & limitations
Ipamorelin
Strengths
- Represents an area of active research interest with growing study volume
Limitations
- Restricted from compounding pharmacies (FDA Category 2)
- Few human trials — most data is preclinical
- Prohibited in competitive sport under WADA
Sermorelin
Strengths
- FDA-approved with established regulatory record
- Strong evidence base (L4)
- Multiple human clinical trials (15+ indexed)
Limitations
- Prohibited in competitive sport under WADA
Representative studies
Ipamorelin
Ipamorelin, a new growth-hormone-releasing peptide, induces growth hormone release in a specific and selective manner
Raun K, Hansen BS, Johansen NL, et al. · Journal of Endocrinology (1998)
Ipamorelin demonstrated true GH selectivity: no cortisol/ACTH/prolactin elevation even at supramaximal doses, establishing it as the cleanest GHRP.
PubMed 9725926Ipamorelin, the first selective growth hormone secretagogue
Johansen PB, Nowak J, Skjærbæk C, et al. · European Journal of Endocrinology (1999)
Confirmed ipamorelin as the first truly selective GH secretagogue, with a selectivity window exceeding 200-fold between GH release and cortisol stimulation.
PubMed 10580762Sermorelin
Two years of continuous subcutaneous infusion of GHRH(1-29)NH2 in GH deficient adults
Vittone J, et al. · Pituitary (1997)
Two years of sermorelin treatment maintained increased IGF-1 levels and improved lean body mass in GH-deficient adults.
PubMed 9452117Sermorelin Acetate Treatment in Growth Hormone Deficient Children: 2-Year Randomized Double-Blind Trial
Laron Z, Parks JS, Adler GK, et al. · Journal of Clinical Endocrinology & Metabolism (1995)
Sermorelin increased mean height velocity from 4.2 to 8.1 cm/year and serum IGF-1 by 247% compared to baseline; sustained over 24 months.
PubMed 7852385Frequently asked
What is the main difference between Ipamorelin and Sermorelin?
Ipamorelin is a selective growth hormone secretagogue that stimulates gh release without significantly affecting cortisol or prolactin. Its primary mechanism is ghrelin receptor agonism. Sermorelin is a growth hormone-releasing hormone analog with a long history of clinical use for gh deficiency diagnosis and therapy. Its primary mechanism is ghrh receptor agonism. The two differ in regulatory status (Banned from Compounding (Category 2) vs FDA Approved), strength of evidence (L3 vs L4), and the primary conditions for which each is researched.
Is Ipamorelin or Sermorelin FDA approved?
Ipamorelin: Placed on FDA Category 2 list in late 2023. Not approved for human use. Sermorelin: Previously FDA-approved as a diagnostic agent for GH deficiency (Geref). The commercial product was discontinued but sermorelin remains available through compounding pharmacies.
How does the evidence base compare?
Ipamorelin has 33 indexed studies (4 human, 18 animal) and is rated Emerging Clinical Evidence. Sermorelin has 51 indexed studies (22 human, 15 animal) and is rated Strong Clinical Evidence. Evidence ratings reflect PeptideMark's L1–L5 methodology based on study type, sample size, and replication.
Can Ipamorelin and Sermorelin be compared directly?
Yes — both compounds share the growth hormone category, meaning head-to-head comparisons are meaningful for the same therapeutic targets. Direct head-to-head trials between peptides are rare, however, so most comparisons rely on separate trial datasets rather than direct RCT data.
Are Ipamorelin and Sermorelin commonly stacked together?
There is no widely documented stacking protocol combining Ipamorelin and Sermorelin in the peer-reviewed literature. Any combination use should be supervised by a qualified clinician familiar with both compounds' pharmacology and contraindications.
Which has a better-documented safety profile, Ipamorelin or Sermorelin?
Ipamorelin has 6 documented side effects (0 serious). Sermorelin has 6 documented side effects (0 serious). Better documentation does not necessarily mean safer — FDA-approved drugs have more rigorous adverse-event reporting, while research-only compounds may appear "cleaner" simply because fewer controlled trials have captured events systematically.
How are Ipamorelin and Sermorelin administered?
Both are administered via subcutaneous. Practical dosing differences come down to frequency, concentration, and titration schedule rather than route of administration.
Which is better, Ipamorelin or Sermorelin?
"Better" depends on the therapeutic goal, regulatory context, and individual response. Ipamorelin is most researched for growth hormone release and body composition; Sermorelin is most researched for growth hormone stimulation and anti-aging. FDA status also matters: Banned from Compounding (Category 2) for Ipamorelin vs FDA Approved for Sermorelin. This page is educational — any decision to use either compound should be made with a qualified clinician who has reviewed your medical history.
Related comparisons
Full profile
Ipamorelin →
Full profile
Sermorelin →